An observational study in Growth Retardation, sponsored by Central Hospital, Nancy, France. Completed. Open to participants aged Up to 12 Months. Per ClinicalTrials.gov, last updated 2022-12-12.
Sponsored by Central Hospital, Nancy, France · Observational
Use of antenatal corticosteroids therapy has increased since the 2000s. The benefits of such a therapy on premature newborns are scientifically and internationally recognized.
Nevertheless, few studies have been conducted to investigate the impact of this antenatal corticosteroid therapy on full-term newborns (> 36 weeks' gestation).
The aim of this study is to compare the birth parameters of full-term newborns exposed or not to antenatal corticosteroid therapy.
All children included in the study were born at the Regional Maternity Hospital of Nancy between January 1, 2014 and December 31, 2020.
One hundred and twenty-one of them were exposed during pregnancy to antenatal corticosteroids therapy and constitute the exposed arm, whereas 242 were not and constitute the non-exposed arm.
Data were collected retrospectively regarding history of pregnancy, birth parameters and neonatal adaptation.
Central Hospital, Nancy, France is the lead sponsor of 778 studies on the registry; 183 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All children included in the study were born at the Regional Maternity Hospital of Nancy between January 1, 2014 and December 31, 2020.
One hundred and twenty-one of them were exposed during pregnancy to antenatal corticosteroids therapy and constitute the exposed arm, whereas 242 were not and constitute the non-exposed arm.
Exclusion Criteria:
Extrated from the population of full-term newborns (\> 36 weeks of amenorrhea + 6 days) between 2014 and 2020 at the Regional Maternity Hospital of Nancy who received at least one course of betamethasone before 34 weeks of amenorrhea for a threat of preterm delivery. Exposure to an antenatal corticosteroid therapy was defined as the administration of at least one course of betamethasone (i.e. two doses of 12 mg, 24 hours apart). in intramuscular, before 34 weeks of amenorrhea, for a threat of premature delivery.
Drug: Betamethasone
came from the population of full-term newborns (\> 36 weeks of amenorrhea + 6 days) between 2014 and 2020 at the Regional Maternity Hospital of Nancy who who had not been exposed to antenatal steroid therapy. Two controls were selected for a case, appaired on the month and year of birth and on the sex of the case patient.
Evaluate the impact of an antenatal corticosteroid therapy on head growth.
head circumference
Time frame: Birth
Evaluate the impact of an antenatal corticosteroid therapy on fetal weight
birth weight
Time frame: Birth
Evaluate the impact of an antenatal corticosteroid therapy on fetal growth
birth lenght
Time frame: birth
Evaluate the impact of an antenatal corticosteroid therapy on neonatal adaptation : APGAR score for each patient
APGAR score
Time frame: birth
Evaluate the impact of an antenatal corticosteroid therapy on risk of hypoglycemia : number of patients with neonatal hypoglycémia
hypoglycemia
Time frame: first 5 days
Evaluate the impact of an antenatal corticosteroid therapy on risk of hypocalcemia : number of patients with hypoglycemia
hypocalcemia
Time frame: first 5 days
Evaluate the impact of an antenatal corticosteroid therapy on neonatal outcome : number of days of hospitalisation after birth
day of hospitalisations after birth
Time frame: first 5 days
Evaluate the impact of an antenatal corticosteroid therapy on eating disorders (number of patients with difficulty to drink)
eating disorders
Time frame: first 5 days
No study locations are listed for this record.
This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Central Hospital, Nancy, France